Mode
Text Size
Log in / Sign up
N/A N=3,504 Prevention

Consumer Perceptions of Cannabidiol (CBD) Health Claims

Perceptions

Enrolled (actual)
3,504
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Perceived Claim Scores — 2.96; 2.81; 2.71; 2.03 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CBD advertisements (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Wake Forest University Health Sciences
Primary completion
Nov 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Perceived Claim Scores
2.96; 2.81; 2.71; 2.03; 1.76; 1.64
SECONDARY
Perceived Product Safety Scores
3.34; 3.11; 2.92
SECONDARY
Appeal Scores
2.82; 2.42; 1.81

Summary

Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may reduce perceptions of harm and increase perceived benefits of use. This study aims to evaluate how consumers perceive real-world CBD advertisements. To that end, we will implement an online survey and randomize adult participants (ages 18-65) to see various advertisements made about CBD to determine if they interpret advertisements as making health claims that are currently prohibited by the FDA.

Eligibility Criteria

Inclusion Criteria

  • Age 18-65
  • US Residents
  • Satisfies one of the following categories:
  • Current CBD users
  • Ever CBD users
  • Non-CBD users
  • Members of the AmeriSpeak™ panel

Exclusion Criteria

  • Non-English speakers
  • Younger than 18 or older than 65
  • Not US residents
  • Not members of the AmeriSpeak™ panel
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06069713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search